Immupharma (IMM) RNS Announcements
Add to Alert list| Date | Time | Source | Announcement |
|---|---|---|---|
| 20 May 2008 | 07:00 AM | Pre-clinical Data | |
| 13 May 2008 | 06:00 AM | Trademark Approval | |
| 08 May 2008 | 07:00 AM | Preliminary Results | |
| 26 Feb 2008 | 07:00 AM | Phase IIb Trial of IPP-201101 | |
| 08 Jan 2008 | 07:00 AM | Novel Drug Candidate | |
| 18 Dec 2007 | 12:51 PM | Directors' Dealings | |
| 06 Dec 2007 | 07:01 AM | Initiation of Phase IIb trial | |
| 16 Nov 2007 | 12:28 PM | Appointment of Nomad | |
| 28 Sep 2007 | 07:02 AM | Interim Results | |
| 22 Aug 2007 | 07:00 AM | Compound Discovery | |
| 20 Aug 2007 | 10:17 AM | AIM Rule 26 | |
| 13 Aug 2007 | 04:17 PM | Directors' Dealing | |
| 06 Aug 2007 | 02:40 PM | Grant of Options | |
| 10 Jul 2007 | 07:01 AM | Pivotal phase II/III trial | |
| 13 Jun 2007 | 02:00 PM | AGM and Board Update | |
| 01 May 2007 | 07:01 AM | Preliminary Results | |
| 27 Apr 2007 | 03:57 PM | Board Appointment | |
| 15 Feb 2007 | 07:00 AM | Appointment of adviser | |
| 07 Feb 2007 | 07:00 AM | Board Changes | |
| 19 Jan 2007 | 08:57 AM | Total Voting Rights | |
| 05 Jan 2007 | 02:27 PM | Issue of Equity | |
| 27 Dec 2006 | 02:53 PM | Total Voting Rights | |
| 21 Dec 2006 | 07:00 AM | Issue of Equity | |
| 30 Oct 2006 | 07:00 AM | Further Phase II Data | |
| 17 Oct 2006 | 07:00 AM | Phase II Data | |
| 02 Oct 2006 | 07:00 AM | FDA Meeting on Lupus | |
| 26 Sep 2006 | 07:00 AM | Interim Results | |
| 01 Aug 2006 | 07:00 AM | Preliminary Results | |
| 05 Jul 2006 | 07:00 AM | Start of phase II trial | |
| 12 Jun 2006 | 05:04 PM | Accounting reference dates | |
| 10 May 2006 | 07:00 AM | Phase 1 Lupus results | |
| 11 Apr 2006 | 07:00 AM | Research Grants | |
| 07 Oct 2004 | 04:00 PM | Resignation of NOMAD | |
| 30 Jun 2004 | 10:48 AM | Final Results | |
| 19 Mar 2004 | 01:30 PM | Interim Results | |
| 18 Sep 2003 | 07:00 AM | Temporary Suspension | |
| 31 Jul 2003 | 01:06 PM | Result of AGM | |
| 27 Jun 2003 | 07:00 AM | Final Results | |
| 28 Mar 2003 | 12:24 PM | Issue of Convertible Loan | |
| 01 Nov 2002 | 04:08 PM | Director Shareholding | |
| 30 Sep 2002 | 03:52 PM | Interim Results | |
| 26 Jul 2002 | 12:57 PM | Result of AGM | |
| 03 Jul 2002 | 03:37 PM | Director Shareholding | |
| 01 Jul 2002 | 07:00 AM | Preliminary Results | |
| 01 Oct 2001 | 02:35 PM | Dir Shareholding - amendment | |
| 01 Oct 2001 | 02:04 PM | Director Shareholding | |
| 28 Sep 2001 | 07:01 AM | Interim Results | |
| 15 Aug 2001 | 05:27 PM | Corporate Action | |
| 14 Aug 2001 | 06:13 PM | Corporate Action - Update | |
| 13 Aug 2001 | 05:57 PM | Corporate Action-Replacement |
ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France.
ImmuPharma listed on AIM under the ticker IMM.
IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.
IMM share price listed in London at 1,190p in 2000.
Latest directors dealings
- 16 hours ago IntegraFin Holding
- 16 hours ago Spirent Communications
- 16 hours ago CRH (CDI)
- 16 hours ago Bezant Resources
- 17 hours ago EJF Investments Ltd NPV